Discrepancies & Conflict Adjudication
HUMAN-IN-THE-LOOP SWITCH REASONING • CROSS-EXAMINATION OF CONTRADICTIONS
FDA Form 1572 Principal Investigator Sign-Off Mismatch
FDA Form 1572 designates Dr. Eleanor Vance as primary sponsor representative, whereas Vendor MSA Amendment 3 names Dr. Marcus Thorne. Discrepancy triggers an automatic clinical trial hold on Phase II Oncology protocols.
$140,000 Spectrometry Lab Contract Auto-Renewal
Apex BioAnalytical master agreement auto-renews for 12 months ($140,000 commitment) on November 15 unless written opt-out is received 30 days prior (October 15). The transition charter lacks a designated signatory.
Compound C-409 Patent Co-Inventor Assignment Gap
Exhibit C (Co-inventor assignment declaration) referenced in the patent memo is absent from the legal archive binder. Threatens priority rights for European patent counterpart filing due December 15.
FDA Form 1572 Principal Investigator Sign-Off Mismatch
FDA Form 1572 designates Dr. Eleanor Vance as primary sponsor representative, whereas Vendor MSA Amendment 3 names Dr. Marcus Thorne. Discrepancy triggers an automatic clinical trial hold on Phase II Oncology protocols.
“Box 1: Sponsor Representative designated as Dr. Eleanor Vance. Box 6: Clinical protocol trial execution managed by Dr. Marcus Thorne.”SOURCE: Regulatory-Audit-Q3-2024.pdf
“Execution Sponsor is hereby reassigned exclusively to Dr. Marcus Thorne effective October 1, 2024.”SOURCE: Counterpart Archival Instrument